UK markets closed

Akebia Therapeutics, Inc. (AKBA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.4650+0.0050 (+0.34%)
As of 02:40PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close1.4600
Open1.4300
Bid1.4600 x 200
Ask1.4800 x 1700
Day's range1.4243 - 1.5686
52-week range0.7800 - 2.4800
Volume2,231,245
Avg. volume3,272,875
Market cap307.058M
Beta (5Y monthly)0.77
PE ratio (TTM)N/A
EPS (TTM)-0.2200
Earnings date23 Aug 2024 - 27 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.00
  • PR Newswire

    Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets

    Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced key updates pertaining to the commercial launch of Vafseo® (vadadustat) Tablets. Akebia will host an investor conference call at 8:00 a.m. ET on Thursday, July 11, 2024.

  • PR Newswire

    Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted five newly-hired employees options to purchase an aggregate of 517,000 shares of Akebia's common stock on June 28, 2024, including an option to purchase 500,000 shares to Erik Ostrowski, Akebia's newly hired Chief Financial Officer and Chief Business Officer. The options were granted as an inducement material to each such employee entering into

  • PR Newswire

    Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

    Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in the H.C. Wainwright 3rd Annual Kidney Virtual Conference on Monday, July 15, 2024. Mr. Butler will present at 9:30 a.m. ET to provide updates on the progress of commercial launch activities for Vafseo® (vadadustat) Tablets.